Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Sevim KahramanIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.ORCID 0000-0002-2880-6589
Kimitaka ShibueIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.
Dario F De JesusIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.
Hyunki KimIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.
Jiang HuIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.
Debasish MannaChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, United States.
Bridget WagnerChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, United States.
Amit ChoudharyChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, United States.
Rohit N KulkarniIslet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, United States.ORCID 0000-0001-5029-6119
Joslin Diabetes Center · USBroad Institute · US
Funding
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
The Human Islet Distribution Coordinating Center (UC4)UC4DK098085 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EVANS-MOLINA, CARMELLA, NILAND, JOYCE CAROL · 2012 to 2017
$25.6M
Development of platforms for beta cell-specific delivery and ligand discoveryU01DK137242 · NIDDK · BROAD INSTITUTE, INC. · PI Amit Choudhary, ROHIT N. KULKARNI · 2023 to 2026
$3.9M
One-compound, one-islet: A high-throughput platform for small-molecule discoveryU01DK123717 · NIDDK · BROAD INSTITUTE, INC. · PI KULKARNI, ROHIT N., WAGNER, BRIDGET K · 2019 to 2022
$3.1M
Development of small molecule-based methods for targeted cargo delivery to beta cellsUC4DK116255 · NIDDK · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT, KULKARNI, ROHIT N. · 2017 to 2017
$2.7M
Development of platforms for sorting, production, editing of beta cellsR01DK132900 · NIDDK · BROAD INSTITUTE, INC. · PI Amit Choudhary, Neal Krishna Devaraj · 2023 to 2026
$2.6M
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetesR00DK135927 · NIDDK · UNIVERSITY OF CHICAGO · PI Dario F De Jesus · 2025 to 2026
$498k
Special BD LSRFortessaS10OD021740 · OD · JOSLIN DIABETES CENTER · PI SERWOLD, THOMAS F · 2016 to 2016
$363k
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetesK99DK135927 · NIDDK · JOSLIN DIABETES CENTER · PI F DE JESUS, DARIO · 2023 to 2024
Pancreatic α-cells secrete glucagon, an insulin counter-regulatory peptide hormone critical for the maintenance of glucose homeostasis. Investigation of the function of human α-cells remains a challenge due to the lack of cost-effective purification methods to isolate high-quality α-cells from islets. Here, we use the reaction-based probe diacetylated Zinpyr1 (DA-ZP1) to introduce a novel and simple method for enriching live α-cells from dissociated human islet cells with ~95% purity. The α-cells, confirmed by sorting and immunostaining for glucagon, were cultured up to 10 days to form α-pseudoislets. The α-pseudoislets could be maintained in culture without significant loss of viability, and responded to glucose challenge by secreting appropriate levels of glucagon. RNA-sequencing analyses (RNA-seq) revealed that expression levels of key α-cell identity genes were sustained in culture while some of the genes such as
Indexed as
Glucagon-Secreting CellsInsulin-Secreting CellsIslets of LangerhansFluoresceinsGlucagonGlucoseHumansInsulinTranscriptomeFluoresceinsGlucagonGlucoseInsulinbiochemistrycell biologychemical biologydiabeteshumanhuman pancreatic isletspseudoisletsα-cells
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Fluorescein-based sensors to purify human α-cells for functional and transcriptomic analyses. · full record | OpenQuestion